Profile data is unavailable for this security.
About the company
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
- Revenue in USD (TTM)0.00
- Net income in USD-47.78m
- Incorporated2017
- Employees54.00
- LocationDesign Therapeutics Inc6005 Hidden Valley Road, Suite 110CARLSBAD 92011United StatesUSA
- Phone+1 (858) 293-4900
- Fax+1 (302) 636-5454
- Websitehttps://www.designtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aldeyra Therapeutics Inc | 0.00 | -44.80m | 286.43m | 10.00 | -- | 3.37 | -- | -- | -0.7538 | -0.7538 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -33.86 | -36.79 | -39.67 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1522 | -- | -- | -- | 39.47 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 190.86m | -16.39m | 288.04m | 203.00 | -- | 0.5322 | -- | 1.51 | -0.2824 | -0.2824 | 3.29 | 9.28 | 0.2967 | 9.30 | 5.30 | 940,187.20 | -2.55 | 6.61 | -2.95 | 7.62 | 93.62 | 90.55 | -8.59 | 15.18 | 4.84 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Absci Corp | 4.21m | -97.67m | 289.57m | 155.00 | -- | 1.45 | -- | 68.83 | -0.9357 | -0.9357 | 0.0402 | 1.76 | 0.0178 | -- | 3.66 | 27,141.94 | -41.42 | -- | -46.85 | -- | -- | -- | -2,321.56 | -- | -- | -157.35 | 0.0269 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Voyager Therapeutics Inc | 163.78m | 25.88m | 296.12m | 162.00 | 9.24 | 0.8966 | 9.57 | 1.81 | 0.5876 | 0.5876 | 2.94 | 6.06 | 0.4545 | -- | 14.29 | 1,011,012.00 | 7.18 | 0.6378 | 8.42 | 0.8203 | -- | -- | 15.80 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| SAGE Therapeutics Inc | 106.40m | -337.59m | 296.69m | 487.00 | -- | 0.5376 | -- | 2.79 | -5.58 | -5.58 | 1.76 | 9.02 | 0.1354 | -- | 5.24 | 218,478.40 | -42.95 | -21.88 | -48.97 | -23.30 | 91.75 | 99.63 | -317.29 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| iTeos Therapeutics Inc | 35.00m | -121.25m | 296.92m | 157.00 | -- | 0.4701 | -- | 8.48 | -3.15 | -3.15 | 0.9064 | 17.29 | 0.05 | -- | 1.43 | 222,929.90 | -17.31 | 5.84 | -18.16 | 7.02 | -- | -- | -346.44 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| Nautilus Biotechnology Inc | 0.00 | -70.21m | 298.84m | 161.00 | -- | 1.34 | -- | -- | -0.561 | -0.561 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -24.29 | -- | -25.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -144.32m | 304.47m | 186.00 | -- | 1.58 | -- | -- | -2.19 | -2.19 | 0.00 | 2.82 | 0.00 | -- | -- | 0.00 | -52.83 | -40.85 | -57.18 | -44.48 | -- | -- | -- | -- | -- | -- | 0.1337 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Aclaris Therapeutics Inc | 27.08m | -37.00m | 308.58m | 91.00 | -- | 2.37 | -- | 11.40 | -0.5198 | -0.5198 | 0.3806 | 1.82 | 0.1352 | -- | 78.61 | 297,582.40 | -18.47 | -47.29 | -20.87 | -53.87 | 53.53 | 44.00 | -136.65 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Kodiak Sciences Inc | 0.00 | -191.62m | 310.43m | 108.00 | -- | 1.67 | -- | -- | -3.65 | -3.65 | 0.00 | 3.52 | 0.00 | -- | -- | 0.00 | -41.64 | -31.73 | -46.43 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Design Therapeutics Inc | 0.00 | -47.78m | 315.38m | 54.00 | -- | 1.25 | -- | -- | -0.8465 | -0.8465 | 0.00 | 4.46 | 0.00 | -- | -- | 0.00 | -17.02 | -- | -17.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| AC Immune SA | 46.22m | -44.97m | 325.51m | 133.00 | -- | 2.22 | -- | 7.04 | -0.4608 | -0.4608 | 0.4783 | 1.48 | 0.2116 | -- | 3.19 | 347,510.10 | -20.59 | -18.25 | -29.04 | -19.52 | -- | -- | -97.29 | -148.29 | -- | -14.57 | 0.0231 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Jasper Therapeutics Inc | 0.00 | -63.53m | 327.63m | 45.00 | -- | 3.92 | -- | -- | -4.75 | -4.75 | 0.00 | 5.58 | 0.00 | -- | -- | 0.00 | -60.56 | -- | -68.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Q32 Bio Inc | 0.00 | -49.66m | 329.37m | 42.00 | -- | 17.94 | -- | -- | -7.44 | -7.44 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -27.86 | -34.98 | -33.25 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.4079 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| AVITA Medical Inc | 60.04m | -57.32m | 337.42m | 207.00 | -- | 27.60 | -- | 5.62 | -2.23 | -2.23 | 2.33 | 0.4664 | 0.7409 | 1.53 | 7.30 | 290,048.30 | -70.74 | -- | -86.14 | -- | 86.46 | -- | -95.47 | -- | 3.37 | -11.27 | 0.7768 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -123.44m | 339.13m | 33.00 | -- | 1.47 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Design Therapeutics Inc's reporting currency: US Dollar USD
28.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Logos Global Management LPas of 30 Sep 2024 | 4.22m | 7.45% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.07m | 3.66% |
| Baker Bros. Advisors LPas of 30 Sep 2024 | 1.74m | 3.08% |
| Point72 Asset Management LPas of 30 Sep 2024 | 1.60m | 2.83% |
| Tang Capital Management LLCas of 30 Sep 2024 | 1.48m | 2.62% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.37m | 2.42% |
| Almitas Capital LLCas of 30 Sep 2024 | 1.32m | 2.34% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 828.67k | 1.46% |
| Geode Capital Management LLCas of 30 Sep 2024 | 758.55k | 1.34% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 690.83k | 1.22% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
